Literature DB >> 2468709

Cytotoxic T lymphocyte recognition of secreted HLA class I molecules.

B Kahn-Perles1, C Barra, J Jehan, D Fourel, M Barad, J L Maryanski, F A Lemonnier.   

Abstract

The cytolytic responses of DBA/2 mice against syngeneic transfected P815 mastocytoma cells expressing either membrane-associated (HLA-Cw3) or -secreted hybrid (HLA-Cw3 x H-2 Q10b) molecules were compared. In spite of the absence of serologically detectable hybrid molecules on their plasma membrane, cells secreting these molecules elicited a CTL response similar to that of cells expressing the membrane associated HLA-Cw3 molecules, in terms of both MHC-restriction and peptide specificity. Together with the observation that syngeneic mice were capable of rejecting the injected secreting cells, these results imply that secreted HLA class I molecules can function as minor histocompatibility Ag and suggest that processing of both the membrane-bound and the -secreted forms of a protein may follow common or overlapping pathways.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2468709

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Protein-specific cytotoxic T lymphocytes. Recognition of transfectants expressing intracellular, membrane-associated or secreted forms of beta-galactosidase.

Authors:  H G Rammensee; H Schild; U Theopold
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

2.  Cells expressing a major histocompatibility complex class I molecule with a single covalently bound peptide are highly immunogenic.

Authors:  E Mottez; P Langlade-Demoyen; H Gournier; F Martinon; J Maryanski; P Kourilsky; J P Abastado
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

3.  H-2-restricted cytolytic T lymphocytes specific for HLA display T cell receptors of limited diversity.

Authors:  J L Casanova; J C Cerottini; M Matthes; A Necker; H Gournier; C Barra; C Widmann; H R MacDonald; F Lemonnier; B Malissen; J L Maryanski
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.